Acasti Pharma Inc. Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Note 15 - Personnel Expenses (Tables)

12 Months Ended

Mar. 31, 2019

					Thirteen- months ended		Month ended		Twelve-month period ended
	March 31, 2019		March 31, 2018		March 31, 2017		March 31, 2017 (Unaudited)		February 28, 2017 (Unaudited)
	$		$		$		$		$
Salaries and other short-term employee benefits		4,144		3,281		2,491		214		2,277
Share-based compensation costs		1,041		929		674		86		588
Total personnel expenses		5,185		4,210		3,165		300		2,865